Author:
Zhuang XiaoMei,Zhang TianHong,Yue SiJia,Wang Juan,Luo Huan,Zhang YunXia,Li Zheng,Che JinJing,Yang HaiYing,Li Hua,Zhu MingShe,Lu Chuang
Funder
Chinese National Science & Technology
Subject
Pharmacology,Biochemistry
Reference47 articles.
1. Phase I study of icotinib hydrochloride (BPI- 2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors;Zhao;Lung Cancer,2011
2. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies;Tan;Lung Cancer,2012
3. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer;Ren;Chin. Med. J.,2011
4. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomized, double-blind phase 3 non-inferiority trial;Shi;Lancet Oncol.,2013
5. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling;Chen;Exp. Opin. Drug Metab. Toxicol.,2015
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献